Synapse - Therapeutic implications of germline testing in patients with advanced cancers

Therapeutic implications of germline testing in patients with advanced cancers Journal Article

Authors:	Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; Cadoo, K.; Liu, Y.; Carlo, M. I.; Latham, A.; Zhang, H.; Kundra, R.; Smith, S.; Galle, J.; Aghajanian, C.; Abu-Rustum, N.; Varghese, A.; O'Reilly, E. M.; Morris, M.; Abida, W.; Walsh, M.; Drilon, A.; Jayakumaran, G.; Zehir, A.; Ladanyi, M.; Ceyhan-Birsoy, O.; Solit, D. B.; Schultz, N.; Berger, M. F.; Mandelker, D.; Diaz, L. A. Jr; Offit, K.; Robson, M. E.
Article Title:	Therapeutic implications of germline testing in patients with advanced cancers
Abstract:	PURPOSE Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. METHODS Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype-directed therapy were determined. RESULTS Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base classification, 9% (n = 1042) had an LP/P variant in a gene with therapeutic implications (4% level 1; 4% level 3B; < 1% level 4). BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%). When limited to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B genetic findings and 3.2% (n = 289) received germline genotype-directed therapy. Germline genotype-directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers. Of BRCA1/2 patients receiving a poly(ADP-ribose) polymerase inhibitor, 45% (84 of 188) had tumors other than breast or ovarian cancer, wherein the drug, at time of delivery, was delivered in an investigational setting. CONCLUSION In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype-directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.
Keywords:	maintenance therapy; genomics; everolimus; olaparib; mutations; efficacy; variants; american-college; medical genetics; cabozantinib
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	24
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-08-20
Start Page:	2698
End Page:	2709
Language:	English
ACCESSION:	WOS:000707994900009
DOI:	10.1200/jco.20.03661
PROVIDER:	wos
PMCID:	PMC8376329
PUBMED:	34133209
Notes:	Article -- Source: Wos